FDA approval for Copiktra capsules

25 September 2018
2019_biotech_test_vial_discovery_big

There was good news yesterday for Massachusetts, USA-based cancer specialist Verastem Oncology (Nasdaq: VSTM), vindicating the company’s faith in an in-licensed blood cancer drug that a former partner had ditched.

The firm’s shares were up 3.3% pre-market yesterday before trading in the stock was halted pending news, and were up 4% to $9.30 before Tuesday’s opening. However, the shares fell back 3.06% to$ 8.62 in early trading today.

The US Food and Drug Administration has approved Copiktra (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology